시장보고서

상품코드

1726270

세계의 분자 이미징 시장 : 규모, 점유율, 동향 분석(모달리티별, 용도별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Molecular Imaging Market Size, Share, & Trends Analysis Report By Modality (Molecular Ultrasound Imaging, Positron Emission Tomography), By Application (Cardiovascular, Neurology), By End Use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 04월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

분자 이미징 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 분자 이미징 시장 규모는 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 4.6%로 성장할 것으로 예상되며, 2030년에는 114억 달러에 이를 것으로 추정되고 있습니다.

시장 성장의 주된 요인으로는 기술진보, 암 유병률 증가, 연구개발 투자 증가 등을 들 수 있습니다.

암, 심혈관 질환, 신경 질환 등의 만성 질환의 유병률 증가에 의해 효과적인 진단 툴이 필요해지고, 분자 이미징 시장의 성장에 크게 공헌할 것으로 기대되고 있습니다. PET (양전자 방출 단층 촬영), SPECT (단일 광자 방출 컴퓨터 단층 촬영), 핵자기 공명(NMR) 분광계와 같은 분자 영상 장치들이 이러한 면에서 특히 효율적입니다.이 첨단 기술은 다양한 질병과 관련된 신진 대사 과정, 분자 활동 및 구조 변화에 대한 자세한 통찰력을 제공합니다.

게다가, 분자 이미징은 비현성 단계에서도 질병의 조기 발견을 용이하게 하고, 적시 개입과 맞춤 치료 계획을 가능하게 합니다.

M&A, 제품 출시, 규제당국의 승인, 제휴, 공동연구, 연구개발(R&D) 활동 등 시장의 주요 기업이 실시하는 전략적 이니셔티브는 분자 이미징 시장의 성장을 가속하는데 중요한 역할을 하고 있습니다. Gateway 초고자장 NMR 센터에 최첨단의 1.2기가헤르츠(GHz) NMR 시스템의 설치에 성공했습니다. 이 GHz급 NMR 시스템은 핵자기 공명(NMR) 분광법의 큰 진보를 상징하는 것으로, 생명 과학이나 재료 과학의 연구에 혁명을 가져오는 것을 목표로 하고 있습니다.

분자 이미징 시장 보고서 하이라이트

모달리티별로는 단일 광자방사형 컴퓨터 단층촬영(SPECT) 부문이 2024년에 43.3%의 점유율을 획득해 우위를 차지했습니다.
핵자기공명(NMR) 스펙트로미터 부문은 2025년부터 2030년까지 CAGR 8.8%로 가장 급성장하는 부문으로 예측되고 있습니다.
용도별로는 세계의 암 이환율의 상승과 고도의 진단 솔루션에 수요 증가에 의해 2024년에 암 분야가 최대 시장 점유율을 차지했습니다.
최종 용도별로는 임상 현장에서의 첨단 화상 기술의 채용이 증가하고 있기 때문에 병원 분야가 2024년에 최대 시장 점유율을 차지했습니다.
화상 진단센터 부문은 대병원에 비해 효율적인 턴어라운드 타임으로 고품질로 전문적인 화상 진단을 제공할 수 있기 때문에 예측 기간 중에 가장 급성장할 것으로 예측되고 있습니다.
북미가 2024년에 41.4%의 점유율을 차지하고 시장을 독점했습니다.

모달리티별 대시보드
분자 이미징 시장 : 모달리티별 변동 분석
세계의 분자 이미징 시장 : 시장 규모와 동향 분석, 모달리티별(2018-2030년)
분자 초음파 이미징
양전자 방출 단층 촬영(PET)
단일 광자 방출 컴퓨터 단층 촬영(SPECT)
핵자기 공명(NMR) 분광계
기타

제5장 분자 이미징 시장 : 용도별 추정 및 동향 분석

용도별 대시보드
분자 이미징 시장 : 용도별 변동 분석
세계의 분자 이미징 시장 : 시장 규모와 동향 분석, 용도별(2018-2030년)
심혈관계
신경학
종양학
호흡기
위장

제6장 분자 이미징 시장 : 최종 용도별 추정 및 동향 분석

최종 용도별 대시보드
분자 이미징 시장 : 최종 용도별 변동 분석
세계의 분자 이미징 시장 : 시장 규모와 동향 분석, 최종 용도별(2018-2030년)
병원
진단 이미지 센터
연구기관

제7장 분자 이미징 시장 : 지역별 추정 및 동향 분석

시장 대시보드:지역별
시장 점유율 분석 : 지역별(2024년 및 2030년)
분자 이미징 시장 : 주요 포인트, 지역별
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

최근 동향과 영향 분석 : 주요 시장 진출기업별
기업, 경쟁의 분류
벤더 상황
- 주요 기업의 히트맵 분석(2024년)
기업 프로파일
- Bruker
- GE HealthCare
- Siemens Healthineers AG
- Koninklijke Philips NV
- Canon Medical Systems Corporation
- Mediso Ltd.
- Cubresa Inc.
- Shimadzu Corporation
- United Imaging Healthcare Co., Ltd.
- Positron

SHW 25.05.27

Molecular Imaging Market Growth & Trends:

The global molecular imaging market size is estimated to reach USD 11.4 billion by 2030, expanding at a CAGR of 4.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The major factors contributing to market growth include technological advancements, increase in prevalence of cancer, and rising investment in R&D. For instance, according to the International Agency for Research on Cancer, approximately 19,976,499 new cancer cases and 9,743,832 cancer-related deaths were reported globally in 2022.

The growing prevalence of chronic disorders such as cancer, cardiovascular diseases, and neurological conditions necessitates effective diagnostic tools, which are expected to significantly contribute to the growth of the molecular imaging market. Molecular imaging devices such as PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), and Nuclear Magnetic Resonance (NMR) Spectrometer are particularly efficient in this regard. These advanced technologies provide detailed insights into the metabolic processes, molecular activities, and structural changes associated with various diseases. They enable healthcare professionals to visualize and assess the extent and characteristics of tumors, cardiac function, and neurological abnormalities with high precision and accuracy.

Moreover, molecular imaging facilitates early detection of diseases, even at subclinical stages, allowing for timely intervention and personalized treatment planning. This proactive approach not only improves patient outcomes but also reduces healthcare costs associated with advanced disease stages and complications.

Strategic initiatives undertaken by major market players, including mergers and acquisitions, product launches, regulatory approvals, partnerships, collaborations, and research and development (R&D) activities, play a crucial role in driving the growth of the molecular imaging market. For instance, in January 2024, Bruker Corporation successfully installed a state-of-the-art 1.2 Gigahertz (GHz) NMR system at The Ohio State University's National Gateway Ultrahigh Field NMR Center. This GHz-class NMR system represents a significant advancement in nuclear magnetic resonance (NMR) spectroscopy, aiming to revolutionize research in life sciences and materials science.

Molecular Imaging Market Report Highlights:

Based on the modality segment, the Single Photon Emission Computed Tomography (SPECT) segment dominated by capturing a share of 43.3% in 2024
The Nuclear Magnetic Resonance (NMR) spectrometer segment is anticipated to be the fastest-growing segment, with a CAGR of 8.8% from 2025 to 2030.
Based on application, Oncology segment accounted for the largest market share in 2024 due to the rising global cancer burden and the growing demand for advanced diagnostic solutions.
Based on end use, Hospitals segment held the largest market share in 2024 due to the increasing adoption of advanced imaging technologies in clinical settings.
The diagnostic imaging centers segment is projected to be the fastest-growing segment over the forecast period, driven by the ability to offer high-quality, specialized imaging procedures with efficient turnaround times compared to larger hospitals.
North America dominated the market with a share of 41. 4% in 2024.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Modality
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.4.5. Details of Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Modality Outlook
- 2.2.2. Application Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
2.3. Competitive Insights

Chapter 3. Molecular Imaging Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Molecular Imaging Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrant
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
  - 3.3.2.1. Political Landscape
  - 3.3.2.2. Technological Landscape
  - 3.3.2.3. Economic Landscape

Chapter 4. Molecular Imaging Market: Modality Estimates & Trend Analysis

4.1. Modality Segment Dashboard
4.2. Molecular Imaging Market: Modality Movement Analysis
4.3. Global Molecular Imaging Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)
4.4. Molecular Ultrasound Imaging
- 4.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Positron Emission Tomography (PET)
- 4.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Single Photon Emission Computed Tomography (SPECT)
- 4.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. Nuclear Magnetic Resonance (NMR) Spectrometer
- 4.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.8. Others
- 4.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Molecular Imaging Market: Application Estimates & Trend Analysis

5.1. Application Segment Dashboard
5.2. Molecular Imaging Market: Application Movement Analysis
5.3. Global Molecular Imaging Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Cardiovascular
- 5.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Neurology
- 5.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.6. Oncology
- 5.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.7. Respiratory
- 5.7.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.8. Gastrointestinal
- 5.8.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Molecular Imaging Market: End Use Estimates & Trend Analysis

6.1. End Use Segment Dashboard
6.2. Molecular Imaging Market: End Use Movement Analysis
6.3. Global Molecular Imaging Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Hospitals
- 6.4.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.5. Diagnostic Imaging Centers
- 6.5.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
6.6. Research Institutes
- 6.6.1. Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 7. Molecular Imaging Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Molecular Imaging Market by Region: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key Country Dynamics
  - 7.4.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.1.3. Competitive Scenario
  - 7.4.1.4. U.S. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.2.3. Competitive Scenario
  - 7.4.2.4. Canada Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.3.3. Competitive Scenario
  - 7.4.3.4. Mexico Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.5. Europe
- 7.5.1. U.K.
  - 7.5.1.1. Key Country Dynamics
  - 7.5.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.1.3. Competitive Scenario
  - 7.5.1.4. U.K. Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.5.2. Germany
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.2.3. Competitive Scenario
  - 7.5.2.4. Germany Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.3.3. Competitive Scenario
  - 7.5.3.4. France Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.4.3. Competitive Scenario
  - 7.5.4.4. Italy Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.5.3. Competitive Scenario
  - 7.5.5.4. Spain Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.5.6. Denmark
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.6.3. Competitive Scenario
  - 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.5.7. Sweden
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.7.3. Competitive Scenario
  - 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.5.8. Norway
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.8.3. Competitive Scenario
  - 7.5.8.4. Norway Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key Country Dynamics
  - 7.6.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.1.3. Competitive Scenario
  - 7.6.1.4. Japan Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.2.3. Competitive Scenario
  - 7.6.2.4. China Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.6.3. India
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.3.3. Competitive Scenario
  - 7.6.3.4. India Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.4.3. Competitive Scenario
  - 7.6.4.4. Australia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.5.3. Competitive Scenario
  - 7.6.5.4. South Korea Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.6.6. Thailand
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.6.3. Competitive Scenario
  - 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.2.3. Competitive Scenario
  - 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.3.3. Competitive Scenario
  - 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 to 2030 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.2.3. Competitive Scenario
  - 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.3.3. Competitive Scenario
  - 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.4.3. Competitive Scenario
  - 7.8.4.4. UAE Market Estimates and Forecasts, 2018 to 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.5.3. Competitive Scenario
  - 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/ Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
- 8.4.1. Bruker
  - 8.4.1.1. Company Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. GE HealthCare
  - 8.4.2.1. Company Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. Siemens Healthineers AG
  - 8.4.3.1. Company Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. Koninklijke Philips N.V.
  - 8.4.4.1. Company Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. Canon Medical Systems Corporation
  - 8.4.5.1. Company Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. Mediso Ltd.
  - 8.4.6.1. Company Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. Cubresa Inc.
  - 8.4.7.1. Company Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Shimadzu Corporation
  - 8.4.8.1. Company Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. United Imaging Healthcare Co., Ltd.
  - 8.4.9.1. Company Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. Positron
  - 8.4.10.1. Company Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives